These results suggest that NPM1 Group1 and Group2 of AML patients indeed have distinct transcription features, and that NPM1 Group1 patients are correlated to FAB M5 subtypes and NPM1 Group2 patients are correlated to FAB M2 subtype. The gene discussed is FANCB; the disease is acute myeloid leukemia.